Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 11Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 2Meningeal Neoplasms 2Lymphoma, Non-Hodgkin 2HER2-positive Breast Cancer 2Stomach Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Meningeal Carcinomatosis 1Hemangiosarcoma 1Colorectal Neoplasms 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × tucatinib × Clear all
NCT07193394 2026-02-23

H3RAKLES

Institut Curie

Phase 2 Recruiting
20 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05673928 2026-01-21

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT05868226 2025-04-04

PRE-I-SPY-PI

QuantumLeap Healthcare Collaborative

Phase 1 Recruiting
124 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡